Point-of-care testing to promote cardiovascular disease risk assessment: A proof of concept study

Updated cholesterol guidelines emphasize multivariable cardiovascular disease (CVD) risk estimation to guide treatment decision-making in primary prevention. This study tested the preliminary feasibility, acceptability and efficacy of point-of-care testing (POCT) and quantitative CVD risk assessment in high-risk adults to increase guideline-recommended statin use in primary prevention. Participants were aged 40–75 years, without CVD or diabetes mellitus, and potentially-eligible for consideration of statins based on estimated 10-year CVD risk from last-measured risk factor levels in the electronic health record. We performed POCT to facilitate quantitative CVD risk assessment with the Pooled Cohort Equations immediately before a scheduled primary care provider (PCP) visit. Outcomes were: physician documentation of a CVD risk discussion and statin prescription on the study date. We also assessed acceptability of the intervention through structured questionnaire. We recruited 18 participants (8 from an academic practice and 10 from a federally-qualified health clinic). After the intervention, 83% of participants discussed CVD risk with their PCP, 47% received a statin recommendation from their PCP, and 29% received a new statin prescription during the PCP visit. Participants reported high levels of satisfaction with the intervention. This study demonstrates that in initial testing pre-visit POCT and quantitative CVD risk assessment appears to be a feasible and acceptable intervention that may promote guideline-recommended statin initiation in primary prevention. Future research with an adequately powered trial is warranted to determine the effectiveness of this approach in clinical practice.

[1]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[2]  Hongmei Zhu,et al.  Is self-monitoring of blood glucose effective in improving glycaemic control in type 2 diabetes without insulin treatment: a meta-analysis of randomised controlled trials , 2016, BMJ Open.

[3]  Jennifer G. Robinson,et al.  Moving Toward the Next Paradigm for Cardiovascular Prevention. , 2016, Circulation.

[4]  A. St John The Evidence to Support Point-of-Care Testing. , 2010, The Clinical biochemist. Reviews.

[5]  Tanya K Bubner,et al.  Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review. , 2010, Family practice.

[6]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Journal of the American College of Cardiology.

[7]  D. Fitzmaurice,et al.  Self-monitoring and self-management of oral anticoagulation. , 2016, The Cochrane database of systematic reviews.

[8]  Trudy van der Weijden,et al.  Barriers to implementing cardiovascular risk tables in routine general practice , 2004, Scandinavian journal of primary health care.

[9]  Stephen D. Persell,et al.  Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial , 2015, Circulation. Cardiovascular quality and outcomes.

[10]  Ralph Weissleder,et al.  Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research , 2016, JACC. Basic to translational science.

[11]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[12]  J. Spertus,et al.  Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide , 2017, JAMA cardiology.

[13]  L. Till,et al.  Assessment of Clinical Pharmacist Management of Lipid-Lowering Therapy in a Primary Care Setting , 2003, Journal of managed care pharmacy : JMCP.

[14]  J. Mckenney,et al.  Office-Based Cholesterol Testing: Impact on Process-of-Care in Patients with Hypercholesterolemia a Pilot Study , 1997 .

[15]  T. Wadden,et al.  Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. , 2014, Journal of the American Pharmacists Association : JAPhA.

[16]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[17]  Dave L Dixon,et al.  Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing. , 2010, Journal of clinical lipidology.

[18]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[19]  H. Krum,et al.  Impact of pharmacist‐conducted home visits on the outcomes of lipid‐lowering drug therapy , 2004, Journal of clinical pharmacy and therapeutics.

[20]  Lauren Haggerty,et al.  Cholesterol Point-of-Care Testing for Community Pharmacies: A Review of the Current Literature , 2017, Journal of pharmacy practice.

[21]  T. Fahey,et al.  Risk scoring for the primary prevention of cardiovascular disease , 2009 .